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esponsibility of InstAbstract Colloidal lipid particles such as solid lipid nanoparticles and liquid crystalline nanoparticles
have great opportunities as drug carriers especially for lipophilic drugs intended for intravenous
administration. In order to evaluate drug release from these nanoparticles and determine their behavior
after administration, emulsion droplets were used as a lipophilic compartment to which the transfer of a
model drug was measured. The detection of the model drug transferred from monoolein cubic particles
and trimyristin solid lipid nanoparticles into emulsion droplets was performed using a ﬂow cytometric
technique. A higher rate and amount of porphyrin transfer from the solid lipid nanoparticles compared to
the monoolein cubic particles was observed. This difference might be attributed to the formation of a
highly ordered particle which leads to the expulsion of drug to the surface of the crystalline particle.
Furthermore, the sponge-like structure of the monoolein cubic particles decreases the rate and amount of
drug transferred. In conclusion, the ﬂow cytometric technique is a suitable technique to study drug transfer
from these carriers to large lipophilic acceptors. Monoolein cubic particles with their unique structure can
be used successfully as a drug carrier with slow drug release compared with trimyristin nanoparticles.
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Many promising drugs are poorly water soluble and lipophilic,
which can lead to difﬁculty in the parenteral administration of
these drugs1. For that reason, lipid nanoparticles have arisen as an
important colloidal carrier system. This importance is based on
their physiological acceptance and the possibility of large-scale
production by high-pressure homogenization1. These nanoparticles
have different physical states (liquid, crystalline and liquid crystal-
line) and sometimes also exist in several crystal modiﬁcations1,2
according to the storage temperature and the type of the lipid used
in their preparation. Lipid nanoparticles may be in the form of a
nanoemulsion or as solid nanoparticles. A major disadvantage of
the lipid nanoemulsions is the difﬁculty in obtaining controlled
drug release due to the liquid state of the carrier. For most drugs, a
rapid release of the drug will be observed3–5. To overcome this
problem, solid lipids instead of liquid oils have been used to obtain
controlled drug release, because drug movement in a solid lipid
should be less than in liquid oil. Solid lipid nanoparticles combine
the advantages of both the lipid nanoemulsion and the controlled
release, which was expected from the solid state of the lipid6,7. To
keep this important advantage of controlling drug release upon
administration, the melting point of the lipid must exceed body
temperature8.
Another important colloidal drug delivery system is particles
with a cubic internal structure. Depending on the concentration of
monoolein in water, monoolein dispersions form different lyo-
tropic liquid crystalline structures9. By the addition of monoolein
to excess water, a bicontinuous cubic phase is formed at room and
body temperature. This cubic phase consists of a pair of
interpenetrating but non-contacting water channels separated by
a single, highly curved continuous lipid bilayer. Due to its unique
structure the cubic phase can accommodate different types of
drugs with different solubility10,11. Furthermore, cubic particles
can be dispersed into nanoparticles which are termed cubosomes.
Cubosomes were obtained from the cubic particles by applying
high shear (e.g., using high pressure homogenization or sonica-
tion) to disrupt a coarse particles of the cubic phase into small,
often submicron-sized particles in the presence of surfactants like
poloxamer9,12. The major drawback of this size-reduction process
is the formation of monoolein vesicles. However, heat treatment of
the homogenized dispersions results in the transformation of
vesicles into cubic particles.
Many methods have been described to investigate the in vitro
drug release of these colloidal drug delivery systems, based on
(ultra)ﬁltration or centrifugation to separate the released drug from
the drug carrier particles5,13–15. All these methods depend on the
use of simple aqueous release media which appears to be of
limited suitability due to the absence of lipophilic compartments as
present in the blood stream. Moreover, these lipid colloidal carriers
incorporate lipophilic drugs, which have a much higher afﬁnity to
the drug carrier than to the release medium. To simulate the
conditions encountered by the drug and drug carriers inside the
body, the transfer from different colloidal carriers such as lipid
nanoparticles into lipophilic acceptor compartments, which mimic
the physiological environment, was studied. For example, release
media was supplemented with albumin or unilamellar vesicles and
oil/water (o/w) emulsion droplets16–21.
In the present study, the transfer from both lipid carriers (solid
lipid nanoparticles and monoolein cubic particles) into the acceptor
o/w emulsion droplets was performed by using a ﬂow cytometric
technique. Through the ﬂow cytometric technique the amount ofdrug in the large acceptor particles can be detected without
interference from the small donor nanoparticles. Thus a separation
step between the donor and acceptor was not required and the
transfer mixture can be analyzed in situ after dilution21. Porphyrin
was employed as a model drug to investigate the transfer behavior
with comparison between the two lipid nanoparticles.2. Materials and methods
2.1. Materials
Triglycerides trimyristin (D114, Dynasan 114) and Miglyol 812
were from Condea Chemie (D-Witten), Poloxamer 407 (Lutrol
F127) was from BASF AG (D-Ludwigshafen), sodium glycocho-
late (SGC) and 5,10,15,20-tetrakis (4-hydroxyphenyl)-21H, 23H-
porphine (porphyrin) were from Sigma-Aldrich (D-Steinheim),
Lipoid S75 was from Lipoid GmbH (D-Ludwigshafen), monoolein
(GMOrphic-801) from Eastman Chemical Company (Kingsport,
TN), methanol was from Carl Roth GmbH (D-Karlsruhe), acet-
onitrile, ethanol and chloroform all from VWR International (D-
Darmstadt), tetrahydrofurane (THF) was from Fisher Scientiﬁc (D-
Nidderau), and Hepes and sodium chloride were from AppliChem
GmbH (D-Darmstadt). Puriﬁed water was prepared by ﬁltration
and deionization/reverse osmosis (Milli RX 20, Millipore,
D-Schwalbach).
2.2. Preparation of the donor monoo`lein dispersions
The monoolein dispersions were prepared from 5% amphiphile
(monoolein and poloxamer) with 12% poloxamer (related to the
total amphiphile amount). Molten monoolein (MO) was mixed
with poloxamer 407 followed by the dropwise addition of the
molten mixture to water while stirring at room temperature22. The
resulting coarse dispersions were kept under magnetic stirring and
protected from light for at least 1 day at room temperature before
homogenization in a microﬂuidizer M-110S (Microﬂuidics, US-
Newton) at 350 bar for 15 min at 40 1C. After homogenization,
fractions of the dispersions were autoclaved at 121 1C in a
laboratory autoclave (Varioklav, 65T, D-Oberschleissheim) for
15 min plus an equilibration time of 5 min. Autoclaving was used
as a source of heat to improve the properties of the dispersions and
convert vesicular structures, which were obtained after the homo-
genization process, into particles of cubic structure22,23.
Loading of porphyrin was performed by adding 500 mL of a
porphyrin stock solution in methanol (10 mg/mL) to 10 mL of the
monoolein cubic particles. The samples were shaken for 3 days at
25 1C in a shaking water bath (Grant OLS 200, Cambridge,
England).
2.3. Preparation of the donor trimyristin solid lipid nanoparticles
The dispersions were prepared from 5% (w/w) trimyristin stabi-
lized with 1.8% (w/w) Lipoid S75 and 0.45% (w/w) sodium
glycocholate (SGC) in an aqueous phase containing 2.25%
glycerol for isotonization and 0.01% thiomersal for preservation.
The preparation was done by high-pressure melt homogenization
using a Microﬂuidizer M-110S (Microﬂuidics, US-Newton)24. S75
and SGC were dispersed/dissolved in the aqueous phase by
magnetic stirring overnight. The matrix lipid and the surfactant-
containing aqueous phase were heated to 70 1C. After melting of
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lipid and the mixture was pre-homogenized for one minute (Ultra-
Turrax T8, IKA Labortechnic, Germany). This crude emulsion was
transferred to the warm (70 1C) high-pressure homogenizer and
treated for 5 min at 500 bar. The resulting hot colloidal emulsion
was allowed to cool to room temperature. Under these conditions
the matrix lipid remains in its liquid state due to supercooling25.
To separate the solid trimyristin nanoparticles from the excess
emulsiﬁer S75, 5 mL samples of the nanosuspensions were
subjected to ultracentrifugation (XL-80 ultracentrifuge, rotor type
SW55 Ti, Beckman Coulter Inc., US-Fullerton) for 1 h at
35,000 rpm and 15 1C. After removing the aqueous supernatant
containing the excess emulsiﬁers the pellet was scraped from the
tube bottom, resuspended in 5 mL of surfactant-free aqueous phase
and sonicated for 10 min at 60 1C.
The trimyristin nanoparticles were loaded with porphyrin
(0.5 mg/mL) after the ultracentrifugation process and removal of
the excess emulsiﬁer (S75). A stock solution of porphyrin was
prepared in methanol (10 mg/mL) and from this stock solution
500 mL was added to 10 mL of the nanoemulsion. The samples
were mixed by shaking for 2 days at 25 1C in a shaking water bath
(Grant OLS 200, Cambridge, England) followed by solidiﬁcation.
2.4. Preparation of the acceptor o/w emulsion droplets
The acceptor o/w emulsion was composed of 5% (w/w) liquid
medium chain triglycerides (Miglyol 812) stabilized with 3% (w/w)
polyvinyl alcohol in an aqueous phase containing 2.25% glycerol
and 0.01% thiomersal21. The emulsion was prepared at room
temperature using an Ultra-Turrax (T8, IKA Labortechnic, Ger-
many) for 15 min. The emulsion was stored at room temperature
and used directly after preparation. For calibration of the ﬂow
cytometer, small fractions of the emulsion were loaded with
different amounts of porphyrin in the same way as described for
the donor lipid nanoparticles.
2.5. Particle size and zeta potential analysis
Particle sizes of the donor lipid nanoparticles with and without the
model drug were measured by photon correlation spectroscopy
(PCS) using a Zetasizer Nano ZS (Malvern Instruments Ltd., UK-
Worcestershire). Ten mL of the dispersions was diluted with 1 mL
of ﬁltered demineralized water and measured at 25 1C at a
scattering angle of 1731. The results of three consecutive measure-
ments of 5 min duration performed after 5 min of equilibration
were averaged. The results are given as the z-average diameter and
the polydispersity index (PDI, measure for the relative width of the
particle size distribution).
The particle sizes of the donor nanoparticles before and after
ultracentrifugation, the donor monoolein dispersions, and the
acceptor o/w emulsion droplets were measured with laser diffrac-
tion (LD) in combination with PIDS (polarization intensity
differential scattering) using a Coulter LS 230 Particle Sizer
(Beckman Coulter, D-Krefeld). Eight consecutive measurements
of 90 s were averaged. The applied evaluation model used the Mie
theory with a refractive index of 1.332 for water and 1.45 for the
sample. The volume distributions of the samples were calculated
and the results are given as the mean particle sizes.
The zeta potential of donor nanoparticles before and after
ultracentrifugation was measured after diluting 10 mL of the
samples with 1 mL 10 mmol/L tris buffer using the same MalvernZetasizer Nano series (Malvern Instruments Ltd., UK-Worcester-
shire). The results of three consecutive measurements each
consisting of 20 runs were averaged.
2.6. Small angle X-ray diffraction measurements of the donor
monoolein dispersions
Small angle X-ray measurements were performed to conﬁrm the
presence or absence of cubic particles in the donor monoolein/
poloxamer dispersions before and after autoclaving. Small-angle
X-ray diffractograms were recorded for 1–2 h in a capillary sample
holder with a SWAX camera based on a Kratky collimator system
(Hecus M. Braun, Optical Systems GmbH, A-Graz) with an Iso-
Debyeﬂex 3003 60 kV generator (Seifert-FPM D-Freiberg), an X-
ray tube (copper anode) FK 61-04 12 and equipped with
2 position sensitive detectors (PSD-50M, M. Braun, D-Garching).
2.7. Determination of the lipid content of the donor trimyristin
nanoparticles by HPLC
HPLC analysis was carried out on the trimyristin lipid nanopar-
ticles because these nanoparticles were subjected to an ultracen-
trifugation process to separate them from the excess emulsiﬁer.
The amount of trimyristin in the nanoparticles and in the super-
natant layer before and after ultracentrifugation was determined
using reversed phase HPLC with evaporative light scattering
detection (Varex MKIII ELSD, Alltech GmbH, D-Unterhaching).
The analysis was performed with a 25 cm 3 mm LiChrocart
column packed with LiChrospher 100-5 RP 18 (Merck KgaA,
D-Darmstadt) in a System Gold 126 HPLC (Beckman Coulter
GmbH, D-Krefeld). Acetonitrile-tetrahydrofurane 55:45 (v/v) was
used as the mobile phase and the isocratic ﬂow rate was set at
1 mL/min. For evaporation of the mobile phase, the temperature of
the detector was adjusted at 91 1C and the ﬂow rate of nitrogen gas
was 2.2 L/min. A calibration curve for trimyristin was obtained
from measurements of standard solutions of trimyristin. In order to
measure the amount of trimyristin in the nanoparticles, small
amounts of the nanoparticle dispersions (before and after ultra-
centrifugation) and the supernatant layers were dissolved in
acetonitrile-tetrahydrofurane 20:80 (v/v) to prepare 1 mL/mL sam-
ples and 100 mL aliquots of these solutions were injected into the
HPLC for analysis. The amount of trimyristin in the samples was
determined from the calibration curve.
2.8. Transfer investigations by ﬂow cytometry
The measurements were performed in a similar way as described
previously21. To choose the conditions for the measurements, the
acceptor emulsion droplets were measured (without drug) in the
ﬂow cytometer. Different amounts of the emulsion droplets were
diluted with puriﬁed water in a measurement tube and subse-
quently measured by ﬂow cytometry. The optimal amount of
emulsion droplets was achieved when a count rate of approxi-
mately 250 events per second was reached. The measurements
were stopped after the detection of 10,000 events. The emitted
ﬂuorescence of porphyrin was detected at the photomultiplier tube
number 4 (FL4) with a wavelength range of 665–685 nm.
Calibration of the ﬂow cytometer was performed by measuring
the ﬂuorescence intensity of acceptor emulsion droplets which had
been loaded with deﬁned amounts of the porphyrin. This calibra-
tion curve was used to calculate the fractions of porphyrin
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ments cleaning steps were introduced to avoid mixing with
residual particles from preceding samples.
The transfer of porphyrin was investigated by mixing different
amounts of the loaded donor particles with 1 mL of the acceptor o/w
emulsion in Eppendorf tubes followed by incubating these tubes in a
water bath shaker at 37 1C (Grant OLS 200, Cambridge, England).
Samples were collected at different time points after mixing and
12 mL of the transfer mixture were diluted with 1 mL puriﬁed water
and subsequently measured at the ﬂow cytometer.
2.9. Transfer kinetics
The curves of the percentage porphyrin transferred from both
donors (solid lipid nanoparticles and monoolein cubic particles) to
the acceptor emulsion droplets, determined using the ﬂow cyto-
metric technique, were exponentially ﬁtted using Microcal Origin
6.0 software (OriginLab Corporation, US-Northampton) and the
exponential function:
Aacc ¼ AfinalA ekt ð1Þ
where Aacc is the percent amount of porphyrin transferred to the
acceptor particles at time t, Aﬁnal is the ﬁnal percent transferred
amount of drug and marks the height of the plateau; A is a pre-
exponential coefﬁcient and k is the rate constant of the transfer.
The equilibrium time was determined by calculating the time
required to reach 99% of the equilibrium amount.Figure 1 (A) LD-PIDS particle size distributions of the original
crystalline nanoparticles (before ultracentrifugation) and the resus-
pended crystalline nanoparticles (pellets after ultracentrifugation).
(B) LD-PIDS particle size distribution of the donor monoolein
dispersions and the acceptor emulsion droplets.3. Results
3.1. Preparation of the donor nanoparticles
The solid lipid nanoparticles were prepared by high pressure
homogenization which led to dispersions with PCS z-average
values around or slightly above 100 nm (Table 1). Crystallization
of trimyristin nanoparticles by storing them at refrigerator tem-
perature resulted in larger particle sizes than for the corresponding
emulsion formulations (stored at room temperature). This effect
can be attributed to a change in particle shape during recrystalliza-
tion of the nanoparticles. The transformation of the spherical
emulsion droplets into platelet-shape crystals resulted in particles
with a larger hydrodynamic PCS diameter25. The particle size of
nanoparticles loaded with the drug model was similar to that of
their unloaded counterparts (Table 1).
After high pressure homogenization, colloidal lipid emulsions
and solid lipid nanoparticles that have been stabilized with the aid
of phospholipids may contain a signiﬁcant fraction of small
unilamellar vesicles (SUV) which was related to the excessTable 1 PCS z-average mean particle size and polydispersity i
ultracentrifugation).
Formulation z-Average 7 SD (
Unloaded
Stored at 23 1C
Nanoparticles before ultracentrifugation 11570.6/0.14
Nanoparticles after ultracentrifugation N.D.
N.D.: not detected.phospholipids6,17,26. Since this study is based on measuring the
drug transfer from triglyceride nanoparticles (not from the
vesicles), an ultracentrifugation step was carried out on the
crystallized nanoparticles to separate them from excess phospho-
lipid vesicles. Similar procedures are often used in the investiga-
tion of parenteral fat emulsions26–28.
In order to determine the effect of the ultracentrifugation
procedure on the particle size of the lipid nanoparticles, particle
size of the resuspended nanoparticles was measured. Moreover,
the mechanical stress upon ultracentrifugation might lead to an
aggregation of the triglyceride nanoparticles. Compared to that of
the non-centrifuged dispersions, the PCS z-average values of the
crystalline nanoparticles had indeed increased after ultracentrifu-
gation and redispersion but the PDI values all remained far belowndices (PDI) of the trimyristin nanoparticles (before and after
nm)/PDI
Loaded with porphyrin
Stored at 4 1C
12270.7/0.16 12370.9/0.17
14170.4/0.11 14271.5/0.11
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distributions (Table 1). A slight shift to larger particle size values
was conﬁrmed by laser diffractometry (LD) in combination with
PIDS (polarization intensity differential scattering) (Fig. 1A). Zeta
potential of the donor nanoparticles before and after ultracentrifu-
gation was 6072.1 mV and 5571.8 mV, respectively. This
negative zeta potential could be attributed to the presence of the
anionic emulsiﬁer SGC in these formulations. Furthermore, this
high potential indicates the stability of these nanoparticles before
and after the ultracentrifugation process.
Fig. 1B illustrates LD-PIDS particle size distributions of the
monoolein dispersions before and after autoclaving. After homo-
genization, the monoolein dispersions were translucent and
homogeneous with monomodal particle size distributions and
mean sizes of about 100 nm. Heat treatment of the monoolein
dispersions led to the aggregation and the transformation of
monoolein vesicles into cubic nanoparticles (cubosomes) which
had milky appearance23,29. The mean particle size of the disper-
sions after autoclaving was about 300 nm.
LD-PIDS of the emulsion droplets shows acceptor particles
with a mean particle size of about 6 mm (Fig. 1B). LD-PIDS of the
acceptor emulsion droplets after 4 months of storage at refrigerator
temperature showed no alterations in the mean particle size, which
indicates the stability of these particles.
3.2. Small angle diffraction measurements of monoolein dispersions
The occurrence of corresponding small angle X-ray reﬂections
conﬁrmed the existence of cubic particles in all autoclaved
dispersions (Fig. 2). In contrast, no reﬂections were observed for
the dispersions before the autoclaving process. According to
earlier results23, these dispersions before autoclaving contain a
high ratio of monoolein vesicles and not cubic particles, which do
not display small angle reﬂections. In all cases, the small angle X-
ray reﬂections observed were characteristic of a P-type cubic
phase. Since the comparison was intended to be carried out
between the solid lipid nanoparticles and the cubic particles, the
transfer experiments were performed from the donor monoolein
dispersions after the autoclaving process (monoolein cubic
particles).
3.3. High performance liquid chromatography of the donor
particles
Since the ultracentrifugation process may lead to a loss of
triglyceride from the formulations, a measurement of the real
triglyceride content in the nanoparticle before and after ultracen-
trifugation was determined by HPLC. Only 77% of the originalFigure 2 Small angle X-ray diffractograms of monoolein/poloxamer
dispersions prepared with 5% amphiphile (monoolein and poloxamer).trimyristin content remained in the re-dispersed nanoparticle
suspensions after ultracentrifugation. About 20% of the trimyristin
was lost into the supernatant during the ultracentrifugation process.
3.4. Investigation of porphyrin transfer
The ﬂow cytometric technique was used to monitor the drug
transfer from the donor monoolein cubic particles and the
trimyristin solid lipid nanoparticles to the acceptor emulsion as
the particle size of the acceptors (about 6 mm) was large enough to
be recognized by the ﬂow cytometer21. Furthermore, the lower size
detection limit of the ﬂow cytometry device (0.5 mm) indicates that
detection of the donor nanoparticles (solid lipid nanoparticles and
cubic particles) with a z-average diameter less than 0.4 mm will not
be possible and thus these small particles will not interfere with the
measurements of the large acceptor particles21.
The drug transfer from the trimyristin solid lipid nanoparticles
to the acceptor emulsion was very rapid and equilibrium was
obtained after about 5 min with the different lipid molar ratios
(Fig. 3A, Table 2). In contrast to donor trimyristin solid lipid
nanoparticles, the transfer from the donor monoolein cubic
particles was moderate and equilibrium was obtained after about
6.5 h with the different lipid molar ratios (Fig. 3B, Table 2).
Fig. 3A and B shows that the ﬁnal amount of porphyrin
transferred from both donors to the acceptor emulsion droplets
was much lower than the theoretical equilibrium values. Assuming
an equal porphyrin distribution between the donor and acceptor,
about 99% of the porphyrin was expected in the different acceptors
at a molar ratio of 1:100 between the donor and acceptor and about
96% at a molar ratio of 1:25. However, the experimentally
determined amount of transferred porphyrin ranged only between
35% and 70% (Table 2).
As expected the ﬁnal amount transferred was increased by
increasing the acceptor-to-donor ratio from 1:25 to 1:100 and this
was observed with both donors.4. Discussion
Solid lipid nanoparticles are at the forefront of colloidal carrier
systems with potential in the delivery of many drugs. Due to their
unique structure and ability to incorporate lipophilic and hydro-
philic drugs, colloidal particles of cubic structure monoolein
(cubosomes) have a great and growing importance in the ﬁeld of
drug delivery. As a result of the importance of these colloidal drug
carriers, it is of great value to evaluate their drug release behavior.
In order to avoid the methodological problems that were
observed with the conventional release methods (such as sample
and separate method and dialysis-based assay), transfer experi-
ments from both donors to lipophilic acceptor emulsion droplets
were used instead of the conventional release techniques. These
acceptor droplets are intended to mimic lipophilic compounds
present in the blood, e.g., lipoproteins.
Flow cytometry is mainly used for cell studies but it has also
been used for the characterization and quantiﬁcation of lipid
particles like liposomes and emulsion droplets30-34. Recently, it
has been used to investigate drug transfer between lipid parti-
cles18,21. Since it does not require a separation step between the
donor and acceptor particles, the ﬂow cytometric method is
characterized by a very good time resolution and can detect large
acceptor particles, which have a particle size of more than
1 mm18,31,33,35. Moreover, the high time-resolution of this
Mohamed Z. Dawoud, Mohamed Nasr168technique allowed the study of the very rapid transfer and many
data points in the rising part of the transfer curves were obtained.
Despite this advantage of the ﬂow cytometric technique, it requires
the use of ﬂuorescent substances as drug models. In addition, one
of the two populations (donor and acceptor) should have large
particles to be detected by the ﬂow cytometer.
A higher rate and amount of porphyrin transfer from the
crystalline solid lipid nanoparticles compared to the transfer from
monoolein cubic particles was observed. This higher drug transfer
might be attributed to the formation of highly ordered structured
particles in the β modiﬁcation upon crystallization, which leaves
little space for the drug molecules, and so leads to the expulsion of
drug to the surface of the crystalline particles36-39. The presence of
the drug molecules at the surface of the crystalline solid lipidFigure 3 (A) Percentage porphyrin transferred from the donor
resuspended crystalline nanoparticles to the acceptor emulsion droplets
with different molar ratios using the ﬂow cytometric technique and
(B) from the donor liquid crystalline monoolein/poloxamer cubic
particles to the acceptor emulsion droplets with different molar ratios
using the ﬂow cytometric technique.
Table 2 Kinetic parameters derived from ﬁtting to the transfer curv
droplets obtained by the ﬂow cytometric technique assuming transfer k
Donor Molar ratio Transfer rate constant K (min1)
Solid lipid nanoparticles 1:25 0.9570.03
1:50 0.8570.04
1:100 0.870.07
Monoolein cubic particles 1:25 0.01770.005
1:50 0.01970.008
1:100 0.02170.005nanoparticles facilitates transfer and decreases the time for transfer
to the acceptor emulsion droplets.
Furthermore, this difference in the transfer course (rate and
amount) could be related to the sponge-like structure of the
monoolein cubic particles, which incorporate the drug in a three-
dimensional network and thus decreases the rate and amount of
drug transferred from this structure. These results are in agreement
with previous observations40, indicating that cubic particles should
be quite useful for rapid uptake because they can rapidly absorb
pollutants (e.g., for water treatment or cosmetic skin protection)
and retain an amount determined by the solute partition coefﬁcient.
These observations supported the high afﬁnity of the lipophilic
porphyrin for the donor monoolein cubic particles and conse-
quently the lower amount and rate of transfer that was observed
from such donor particles.
Another explanation of the slow release from cubic particles in
comparison with the solid lipid nanoparticles is the unique
structure of the cubic particles, which have a great speciﬁc
bilayer/water interfacial area (500–600 m2/g lipid)41. As men-
tioned before42, the interfacial area (lipid/water interface) plays an
important role in the transfer of porphyrin to the different acceptor
particles. This great interfacial area of the cubic particles leads to
the mobility of the drug molecules within the bilayer and decreases
diffusion out of this unique structure.
As observed with both donors, the transfer stopped at concen-
trations far below an equal distribution between the donor and
acceptor. Wiehe and his coworkers42 reported that the transfer of
temoporﬁn, which has a similar structure to porphyrin, was limited
only to the interface as a result of this amphiphilicity. As a result
of this amphiphilicity and the limited size of the large acceptor
particles, saturation might occur and transfer might therefore stop
at a lower level than was previously assumed21.
For both donors, an increase in the acceptor-to-donor ratio led
to an increase in the ﬁnal amount of porphyrin transferred. This
observation was not unexpected and can be explained by the
increase in the number of the acceptor particles relative to the
donor particles.5. Conclusions
Colloidal particles from monoolein dispersions known as cubo-
somes can be successfully used as a drug carrier with slow drug
release compared to trimyristin solid lipid nanoparticles. There-
fore, it is better to use monoolein cubic particles rather than
trimyristin solid lipid particles when sustained drug release is
required. Compared to commonly applied release methods, the
transfer to a lipophilic acceptor compartment is better than the
commonly applied release methods. Moreover, ﬂow cytometry is a
suitable technique to study the transfer of porphyrin from thees of porphyrin from the different donors to the acceptor emulsion
inetics according to equation (1).
Final percentage transferred (%) Equilibrium time R2 for ﬁtting
3371.1 4.4 min 0.983
4770.9 5.4 min 0.985
6571.5 5.5 min 0.987
3271.9 7 h 0.988
4471.2 6.5 h 0.992
5471.3 6 h 0.987
Comparison of drug release using ﬂow cytometry 169different drug carriers to the lipophilic acceptor as it mimics lipid
compartments in the body.
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